NCT00434629 - Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

B-cell LymphomaNon-Hodgkin's Lymphoma

Interventions

DRUG

Bexxar

"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."

Trial Locations (1)

19104

Abramson Cancer Center, University of Pennsylvania, Philadelphia